What is B. Riley’s Forecast for Altimmune Q1 Earnings?

Altimmune, Inc. (NASDAQ:ALT) – Equities research analysts at B. Riley issued their Q1 2025 earnings per share (EPS) estimates for Altimmune in a research note issued to investors on Wednesday, November 13th. B. Riley analyst M. Mamtani expects that the company will post earnings of ($0.41) per share for the quarter. B. Riley currently has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Altimmune’s current full-year earnings is ($0.54) per share. B. Riley also issued estimates for Altimmune’s FY2025 earnings at $0.73 EPS.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.03. Altimmune had a negative return on equity of 52.60% and a negative net margin of 199,076.92%. The business had revenue of $0.01 million for the quarter. During the same period in the prior year, the firm posted ($0.39) EPS.

Several other research firms have also recently weighed in on ALT. UBS Group initiated coverage on Altimmune in a research report on Tuesday. They issued a “buy” rating and a $26.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Altimmune in a research report on Thursday. Finally, Evercore ISI upgraded Altimmune to a “strong-buy” rating in a research note on Friday, August 9th. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $20.00.

Altimmune Trading Down 11.2 %

ALT stock opened at $8.46 on Thursday. The stock’s fifty day simple moving average is $6.99 and its two-hundred day simple moving average is $6.90. Altimmune has a 1-year low of $2.34 and a 1-year high of $14.84. The stock has a market cap of $600.91 million, a P/E ratio of -5.45 and a beta of 0.09.

Insider Buying and Selling at Altimmune

In related news, Director David Drutz sold 16,011 shares of the company’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $6.90, for a total transaction of $110,475.90. Following the sale, the director now owns 41,958 shares of the company’s stock, valued at approximately $289,510.20. This represents a 27.62 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Farallon Capital Management LLC boosted its stake in Altimmune by 1,282.4% during the first quarter. Farallon Capital Management LLC now owns 470,000 shares of the company’s stock valued at $4,785,000 after buying an additional 436,000 shares during the period. Knoll Capital Management LLC lifted its stake in Altimmune by 183.6% during the first quarter. Knoll Capital Management LLC now owns 567,219 shares of the company’s stock worth $5,774,000 after purchasing an additional 367,219 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Altimmune by 142.9% during the second quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company’s stock worth $3,791,000 after purchasing an additional 335,444 shares during the last quarter. Bellevue Group AG lifted its stake in Altimmune by 43.9% during the third quarter. Bellevue Group AG now owns 863,660 shares of the company’s stock worth $5,303,000 after purchasing an additional 263,660 shares during the last quarter. Finally, SG Americas Securities LLC lifted its stake in Altimmune by 542.8% during the second quarter. SG Americas Securities LLC now owns 254,571 shares of the company’s stock worth $1,693,000 after purchasing an additional 214,968 shares during the last quarter. 78.05% of the stock is currently owned by hedge funds and other institutional investors.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.